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Abstract

The impact of drug–drug interactions (DDIs) between interferon-free direct acting antiviral (DAA) regimens and
antiretrovirals (ART) among HIV/HCV co-infected individuals in clinical practice settings is unknown. A singlecenter, retrospective chart review of co-infected patients was conducted from June 2014 to February 2015.
Significant interactions between simeprevir (SMV), ledipasvir (LDV), and paritaprevir/ritonavir/ombitasvir plus
dasabuvir (3D regimen) with ART were identified based on available literature. SMV had the largest number of
DDIs and was further investigated to determine the feasibility of ART switch to allow for DAA use. Of 127
subjects, 23% had advanced liver disease; 86% of those with known HCV genotype were HCV genotype 1. An
ART switch allowing use of SMV, LDV, and 3D regimen was recommended in 97/127 (76%), 81/127 (64%), and
91/127 (72%) patients, respectively. Subjects on PI/r regimens had limited options for ART switch, with 40% of
these patients unable to be switched to an ART regimen that avoided the use of a PI. In conclusion, the majority of
HIV/HCV co-infected patients will be recommended to switch ART prior to use of interferon-free, DAA regimens, and an ART switch may not be feasible for more than a third of patients on a boosted PI. DDIs between
ART and DAAs represent an additional barrier to treatment efficacy in clinical practice settings that are unaccounted for in clinical trials.

Introduction

A

lthough effective antiretroviral therapy (ART)
for the human immunodeficiency virus (HIV) has significantly improved survival,1–4 liver disease continues to be
a substantial source of morbidity and mortality among HIVinfected individuals. In the US, much of the burden for endstage liver disease, hepatocellular carcinoma, and liver
transplantation is due to hepatitis C virus (HCV) infection.5–8
End-stage liver disease is currently a leading cause of death in
this population.9
Approximately one-third of those infected with HIV are
concomitantly infected with HCV.6 Compared to HIVuninfected individuals, untreated HCV infection in an HIV/
HCV co-infected population results in accelerated liver disease progression, higher rates of end-stage liver disease, and
more reduced life expectancy.10 Successful HCV therapy is
defined as achieving an undetectable HCV RNA 12 weeks
after the completion of treatment (SVR12). This is associated

with a reduction in morbidity and mortality due to liver
failure and hepatocellular carcinoma.11 Historically, older
regimens containing pegylated interferon alfa and ribavirin
had low efficacy (SVR12 14–38%) and were poorly tolerated
by HIV/HCV co-infected individuals.12–14 Consequently,
less than 15% of co-infected patients had received treatment
for HCV as of 2011.15
The landscape of hepatitis C treatment was transformed
with the approval of sofosbuvir (SOF), an NS5B inhibitor,
and simeprevir (SMV), an NS3/4A protease inhibitor, in
2013. For the first time, an all oral, interferon-free HCV
treatment option became available. In October 2014, a single
tablet combination pill of sofosbuvir and ledipasvir (SOF/
LDV), an NS5A inhibitor, was approved. This regimen has
rapidly emerged as the preferred option for HCV genotype 1
due to ease of use, high SVR rates, and tolerability.18–20 More
recently, dasabuvir (NS5B inhibitor taken twice a day) in
addition to the once-daily combination pill of ombitasvir
(NS5A inhibitor), paritaprevir (NS3/4A protease inhibitor),
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and ritonavir (utilized as a boosting agent for paritaprevir)
became available in December 2014 (3D regimen). The
American Association for the Study of Liver Diseases, Infectious Diseases Society of America, and the International
Antiviral Society-USA (AALSD/IDSA/IAS-USA) released a
joint guideline in 2013 which has been updated to recommend all three of these regimens as viable options with
similar efficacy for treatment-naı̈ve and experienced individuals with HCV Genotype 1 or 4.16
Clinical decision making regarding the most appropriate
DAA therapy is left largely to individual HCV treatment
providers. One significant factor that should influence this
decision is the presence of drug–drug interactions (DDIs).
This is particularly important among HIV/HCV co-infected
individuals receiving antiretroviral therapy. Sofosbuvir,
ombitasvir, and dasabuvir have few DDIs. In contrast, simeprevir and paritaprevir have DDIs with several antiretrovirals as they undergo oxidative metabolism by the
cytochrome P450 (CYP) 3A enzyme subfamily. Simeprevir
and paritaprevir levels will be altered by inducers or inhibitors of CYP3A4, and both inhibit enzymes such as organic anion transporters (OAT).21,22 This has resulted in a
recommendation to avoid simeprevir and paritaprevir coadministration with HIV protease inhibitors (PI), cobicistatcontaining regimens, or certain non-nucleoside reverse
transcriptase inhibitors (NNRTIs) such as efavirenz (EFV),
nevirapine, and etravirine because these agents increase or
decrease the levels of these DAAs beyond what is considered safe and efficacious.21–23
SOF/LDV was anticipated to have much less drug–drug
interactions than SOF/SMV as LDV is not metabolized by the
CYP enzyme family.23 However, LDV may increase levels of
tenofovir disoproxil fumarate when used in conjunction with
efavirenz, a ritonavir-boosted HIV protease inhibitor, or elvitegravir boosted by cobicistat. The safety of increased tenofovir
levels in this situation is not yet established, but it is currently
recommended to avoid tenofovir in combination with these
specified ART during treatment with SOF/LDV.22,23 The 3D
regimen contains the CYP3A4 inhibitor ritonavir as a boosting
agent for paritaprevir. The study protocol for TUROQUOISE I,
which evaluated the efficacy of this treatment in co-infected
patients, allowed only raltegravir or atazanavir (without additional ritonavir) based regimens.24. Other ARTs are not recommended for concomitant use due to concerns of altered
drug levels or additive QTc prolongation22,25
Providers face many challenges if an ART switch is recommended to avoid DDIs with DAAs The first challenge is
the risk of inappropriate ART to accommodate anti-HCV
therapy, which may put patients at risk for: (a) HIV virologic
failure; (b) development of resistance in both HIV and hepatitis C viruses; and (c) a potential for increased adverse
effects leading to discontinuation and non-adherence with
therapy. Additionally, both patients and providers may be
reluctant to switch ART regimens.
The intent of this study was to determine the need for
antiretroviral therapy switch prior to initiation of HCV
DAAs, and the feasibility of ART switch to allow for DAA
use. It was hypothesized that the majority of HIV/HCV coinfected patients considered for such treatment will be recommended to switch ART. We additionally hypothesized
that the majority of patients on a PI-based ART regimen
would be difficult to switch due to HIV drug resistance.
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A retrospective chart review was conducted at the University of Pittsburgh Medical Center’s HIV Adult Primary
Care Center. The study received exempt IRB approval from
the Review Board of the University of Pittsburgh. All patients
with HIV and active HCV > 18 years old and seen at the
center at least one time between January 2013 and August
2014 were included in the study. Exclusion criteria included
spontaneous clearing of HCV as demonstrated by an undetectable HCV RNA following a positive HCV antibody,
SVR12 previously achieved through use of peg-interferon,
ribavirin, boceprevir, or telaprevir, and current enrollment in
another clinical trial for HCV treatment. Demographic data
and information regarding the patient’s ART regimen was
collected. Patients not currently on ART were included in the
study. Liver staging was done with the APRI (AST to Platelet
Ratio) index. Advanced liver disease was defined as APRI
index ‡ 1 and/or radiographic findings of cirrhosis.29,30
Three pharmacists with infectious disease experience (AP,
RC, and TG) reviewed the medication list of all patients to
identify interactions between SMV, LDV, 3D regimen, and
ART. To aid this review, the DAA package insert,21,22,24
University of Liverpool HIV-Interaction Drug Charts,31 and
AASLD/IDSA/IAS-USA Hepatitis C Treatment Guidelines23 were used. If sources conflicted, AASLD/IDSA/IASUSA recommendations were considered to be the most relevant to clinical practice. If a patient’s current ART was
incompatible with DAA use due to a DDI, this individual was
recommended for ART switch (Table 1).
SMV had the largest number of DDIs and was further
investigated to determine the feasibility of ART switch to
allow for DAA use. If DDIs limiting co-administration of
SMV and the patient’s ART regimen were noted, previous
HIV genotype reports and medication history were reviewed
by a team consisting of previously mentioned pharmacists
(AP, RC, and TG) and two HIV specialist physicians (RP and
PV) to determine if switching to an alternative but effective
ART regimen would be feasible. Feasibility was defined as
the ability to safely change ART to a regimen expected to
effectively suppress HIV viral load based on treatment history and viral resistance patterns. The scope of our investigation was limited to treatment history and drug resistance
and did not incorporate renal function, patient preference,
financial constraints, or other factors typically considered

Table 1. Antiretroviral Therapy (ART)
Regimens Without Clinically Significant
Interactions with Direct-Acting
Antivirals (DAAs)a
DAA
Simeprevir
Ledipasvir

Paritaprevir/r

Safe ART
RAL, RPV, T20, MVC,
TDF, FTC, 3TC, ABC
All regimens except:
 EVG/cobi + TDF
 EFV + TDF
 PI/r + TDF
RAL, TDF, FTC, 3TC, ATV, T20

a
As per drug package inserts and AASLD/IDSA/IAS/USA HCV
Treatment Guidelines.
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when changing ART. Cases in which a switch was not
deemed feasible were reviewed a second time by both HIV
specialist physicians to assure all possible ART regimens
were considered.

Table 3. Need for Antiretroviral Therapy (ART)
Switch Prior to Direct Acting Antiviral Use
in HIV/HCV Co-Infected Adults Based
on Potential for Drug–Drug Interactions

Results

In total, 161 patients were reviewed for inclusion. Of these,
34 had characteristics that excluded them from the study. The
most common reason for exclusion was lack of follow-up at
the clinic within the specified time period. An additional six
patients were deemed ineligible due to treatment with boceprevir as part of a clinical trial. Ultimately, 127 were found to
have a current HCV infection while actively receiving care
from the clinic. Baseline patient characteristics and distribution of ART regimens are shown in Table 2. An ART
switch allowing use of SMV was recommended in 97/127
(76%) patients. For LDV and 3D regimen, an ART switch
was recommended in 81/127 (64%) and 91/127 (72%), respectively (Table 3).
In terms of ART substitutions, individuals with viral susceptibility to efavirenz may be assumed to also have sensitivity to rilpivirine, and a one-to-one switch between these
agents was deemed safe. A straightforward substitution in
this manner could be made in 47/97 (48%) of patients. For the
remaining patients (mostly on a PI), a switch following HIV
expert opinion was deemed safe in 32/97 (33%), while safe
switch was not possible in 18/97 (19%) due to archived HIV
drug resistance mutations.
Notably, for 40% of patients on a PI, an ART switch was
not feasible. This was primarily due to use of salvage regimens where the PI/r had become indispensable. All patients
deemed unable to switch ART were known or predicted to

Table 2. Baseline Characteristics of HIV/HCV
Co-infected Adults at a Single-Center
HIV Primary Care Clinic in 2013–2014

Clinical
characteristic

All
patients
N (%)
N = 127

Age, median years
54
Sex, male
90 (71%)
Race, African
69 (54%)
American
Known HCV
81 (86%)
genotype 1a
CD4 < 200 cells/mm3 14 (11%)
HIV viral load > 200 22 (17%)
Advanced liver
29 (23%)
disease
Not on ART
8 (6%)
2 NRTI + additional agent
Efavirenz
45 (35%)
Rilpivirine
8 (6%)
Raltegravir
14 (11%)
Elvitegravir
2 (2%)
Boosted PI
44 (35%)
Other
6 (5%)

Recommended Recommended
switch—
switch—
feasible
not feasible
N (%)
N (%)
N = 79
N = 18
56
54 (68%)
47 (59%)

55
15 (83%)
11 (61%)

48 (83%)

15 (100%)

10 (13%)
15 (19%)
19 (24%)

3 (17%)
3 (17%)
5 (28%)

–

–

45 (57%)
–
–
2 (3%)
26 (33%)
6 (8%)

–
–
–
–
18 (100%)
–

a
An HCV genotype was available in only 94 patients.
All percentages have been calculated using the N stated in the
second row of each column.

Simeprevir
Ledipasvir
Paritaprevir/r

ART switch
recommended
N (%)

ART switch
not recommended
N (%)

97 (76%)
81 (64%)
91 (72%)

30 (24%)
46 (36%)
36 (28%)

have high levels of HIV drug resistance in which a safe
switch could not be made to a regimen which would avoided
the use of a boosted PI. Among patients who were unable to
switch, 28% had evidence of advanced liver disease.
Discussion

Managing DDIs for HCV treatment in HIV co-infected
patients on ART can be complex and challenging. This study
found that the majority of HIV/HCV co-infected patients at our
center will be recommended to switch ART prior to use of any
interferon-free DAA regimen. Additionally, for over a third of
patients on a PI, an ART switch to accommodate use of DAAs
did not prove feasible. Our study also highlights that 28% of
individuals unable to switch ART had evidence of advanced
liver disease and would meet high priority treatment criteria
per the AASLD/IDSA/IAS-USA HCV guidelines.16
Implications on choice of HCV therapy among
HIV-infected individuals

These findings highlight the complexity of treating HCV,
even with the new DAA’s, and are highly significant to real
world HIV clinical practice settings. To make this research as
relevant as possible, only sources that would commonly be
available, such as the AASLD/IDSA/IAS-USA guidelines
and drug package inserts, were consulted when identifying
DDIs. As the AASLD/IDSA/IAS-USA guidelines do not
indicate a preference as to which DAA regimen should be
used for the treatment of HCV, choosing the most appropriate
DAA therapy in the face of DDIs becomes a clinical decision
that should consider several elements. First, the level of urgency for HCV treatment must be balanced with the severity
of the DDI. This evaluation should incorporate the degree of
liver fibrosis, other extrahepatic comorbidities, and the duration of HCV treatment indicated.
The use of ledipasvir is not recommended in combination
with tenofovir and efavirenz, a ritonavir-boosted HIV protease
inhibitor, or elvitegravir boosted by cobicistat due to an increase in tenofovir levels. However, the predicted increases in
tenofovir may not be clinically significant as tenofovir levels
do not correlate well with intracellular toxicity,32 particularly
over a short treatment course of 8–12 weeks. For the purposes
of this study, individuals on tenofovir in combination with
efavirenz, protease inhibitors, or cobicistat containing agents
were recommended for ART switch prior to use with SOF/
LDV. Preliminary data from the ION-4 study suggests use of
regimens containing tenofovir and efavirenz is actually well
tolerated in co-infected patients.33 Further experience with the
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concomitant use of these medications in the clinical practice
setting will reveal the true significance of this interaction.
For individuals who do not require immediate treatment, a
potential solution in the FDA review pipeline includes the
NS5A inhibitor, daclatasvir, in combination with sofosbuvir
for HCV genotypes 1–4.34 Daclatasvir is similar to SMV in
that it undergoes metabolism by the CYP3A4 enzyme subfamily. However, daclatasvir may be dose-adjusted to accommodate concomitant antiretrovirals: 30 mg with ritonavir
or cobicistat-boosted agents, 90 mg with NNRTIs except rilpivirine.35,36 No dose adjustment is required with raltegravir,
dolutegravir, rilpivirine, or NRTIs including tenofovir. Data
from the Phase III, ALLY-2 study in HIV-HCV co-infected
patients showed SVR12 rates of 97% in treatment-naı̈ve and
experienced patients following 12 weeks of therapy.37

effective in practice for co-infected patients due to the obstacle
posed by DDIs. Our results illustrate a strong need for treatment providers with expertise in both HIV and HCV to diminish the possibility for loss of HIV virologic suppression
and HCV treatment failure. As only 59% of HIV clinicians
report actively managing HIV/HCV co-infection,41 the use of
a team approach including both a clinical pharmacist and
physician is an effective way to address the barriers described
by this article. Models for capacity building to expand access
to this expertise are of urgent need.

Future relevance of simeprevir

Author Disclosure Statement

In the various phase III ION trials for approval of SOF/LDV,
baseline NS5A resistance was detected in 11–18% of participants.18–20 This group tended to have a lower SVR12 rate of
89–90% (as compared to rates as high as 98% overall). Resistance not present at baseline was also seen to develop during
the course of treatment for a small proportion of virologic
failures. With widespread use of this regimen in patients of
varying complexity, it is possible that treatment failure will
occur in practice more often than predicted in the clinical trials.
Cross-resistance to all NS5A inhibitors is likely to occur if
mutations develop,38,39 leaving SOF/SMV as a second-line
option for those who have previously failed this type of therapy.
As a result, SMV is likely to remain relevant in the future.
However, previous treatment failure on a NS3/4A protease inhibitor regimen and the inability to safely change ART to accommodate SMV would represent a significant barrier to its use.
Limitations of this study

As this is a single-center study, results may be limited to
the patient population at our specific HIV Primary Care
Clinic. This study was additionally limited by the consideration of only HIV drug resistance and treatment history when
evaluating for safety and efficacy of ART switch. In practice,
patient preference, need for ART dose adjustment, and other
DDIs such as those between atazanavir or rilpivirine and
acid-suppressing agents would also need to be weighed when
making such a decision. Another limitation is our inclusion of
patients with an unknown HCV genotype in our analysis.
While the reviewed interferon-free DAA treatments would
not necessarily be applicable to all HCV genotypes, given
that genotype 1 accounted for 86% of patients whose genotype was known, we felt it was valuable to include these
patients in our analysis. Additionally, these findings will be of
relevance with the emergence of future therapies with extended or pangenotypic activity.
Conclusions

This study shows that DDIs between ART and DAAs
continue to represent an additional barrier to reducing the gap
between efficacy and effectiveness which should not be
overlooked. Although HIV/HCV co-infected patients now
achieve SVR12 rates comparable to those of mono-infected
patients in clinical trials, these anti-HCV therapies may be less
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